These findings suggest that YAP/TAZ-S100B axis may serve as a therapeutic target in humans to activate inert and metabolically unhealthy visceral WAT and improve glucose homeostasis under diet-induced obesity and aging conditions. This evidence concerns the gene S100B and obesity disorder.